KENNEDY DISEASE (SBMA)

Kennedy Disease (SBMA) — an X-linked motor neuron disease that mimics ALS but with decades-longer survival, where molecular diagnosis transforms a devastating ALS prognosis into a manageable chronic condition.

Whole genome sequencing detects the CAG trinucleotide repeat expansion in the androgen receptor (AR) gene that causes Kennedy disease — the single test that distinguishes SBMA from ALS and changes the prognosis from years to decades.

About this condition

Kennedy Disease

Kennedy disease (spinal and bulbar muscular atrophy, SBMA) is an X-linked neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor gene (AR, chromosome Xq12). Normal AR contains 10-35 CAG repeats; SBMA occurs with 38-62 repeats, producing a polyglutamine-expanded AR protein that is toxic to lower motor neurons and dorsal root ganglia in an androgen-dependent manner. SBMA affects approximately 1 in 30,000-50,000 males. Females carrying the expansion are typically asymptomatic carriers due to X-inactivation, though rare homozygous affected females have been reported.

SBMA typically presents in males aged 30-50 with slowly progressive proximal muscle weakness and atrophy, bulbar symptoms (dysarthria, dysphagia, tongue fasciculations), prominent facial fasciculations (perioral twitching — nearly pathognomonic), hand tremor, muscle cramps, and gynecomastia. Sensory neuropathy is often present but subclinical. The critical diagnostic distinction is from ALS: SBMA is frequently misdiagnosed as ALS on initial evaluation because both conditions cause upper and lower motor neuron signs with fasciculations. However, SBMA prognosis is dramatically different — median survival exceeds 20 years from onset, and many patients survive into their 70s and 80s.

No disease-modifying therapy is currently available for SBMA, though clinical trials of androgen-reducing therapies (leuprorelin/dutasteride), antisense oligonucleotides targeting the polyglutamine-expanded AR, and gene-silencing approaches are ongoing. Supportive management includes physical therapy, speech therapy for dysphagia (aspiration pneumonia is the leading cause of death), fall prevention, and cardiac monitoring (subclinical cardiomyopathy occurs in some patients). The management approach is fundamentally different from ALS — SBMA does not require urgent ALS-specific interventions (riluzole, edaravone, tofersen) and benefits from the extended treatment and planning timeline.

Gynecomastia (breast enlargement) in a male with motor neuron disease is a strong clinical clue for SBMA — it is caused by androgen insensitivity from the expanded AR. ALS does not cause gynecomastia.

Gene locus: AR (Xq12) — CAG repeat expansion (38-62 repeats pathogenic)

Distinguishing SBMA from ALS transforms the prognosis from 2-5 years (ALS) to 20+ years (SBMA). A single genetic test — the AR CAG repeat — makes this life-changing distinction.

ALS misdiagnosis causes devastating psychological harm — SBMA patients told they have ALS receive a falsely terminal prognosis

Multiple case series document SBMA patients initially diagnosed with ALS who lived with a terminal diagnosis for years before genetic testing revealed SBMA. The psychological impact — on the patient, spouse, and family — of being told you have a disease with 2-5 year median survival, when you actually have a condition with 20+ year survival, is profound. AR CAG repeat testing should be performed on any male diagnosed with motor neuron disease, particularly those with bulbar onset, facial fasciculations, gynecomastia, or slower-than-expected progression.

X-linked inheritance means daughters of affected males are obligate carriers — genetic counseling for the next generation requires confirmed diagnosis

Every daughter of an SBMA-affected male inherits the expanded AR allele and is a carrier. Each of her sons has a 50% chance of being affected. Carrier identification enables reproductive counseling, prenatal diagnosis, and informed family planning. Without molecular SBMA diagnosis in the proband, the family may be counseled based on an ALS diagnosis — which is typically sporadic with low recurrence risk — providing falsely reassuring genetic counseling. Whole genome sequencing confirms the X-linked inheritance pattern and enables accurate cascade testing.

Kennedy Disease (SBMA) — an X-linked motor neuron disease that mimics ALS but with decades-longer survival, where molecular diagnosis transforms a devastating ALS prognosis into a manageable chronic condition.

Kennedy Disease

Distinguishing SBMA from ALS transforms the prognosis from 2-5 years (ALS) to 20+ years (SBMA). A single genetic test — the AR CAG repeat — makes this life-changing distinction.

ALS misdiagnosis causes devastating psychological harm — SBMA patients told they have ALS receive a falsely terminal prognosis

X-linked inheritance means daughters of affected males are obligate carriers — genetic counseling for the next generation requires confirmed diagnosis

Others in Neurological

One test. A lifetime of answers.